PF-Atlas › Clinical Trials › NCT02096107
Novartis Everolimus Transition
Everolimus · Phase 4
Registry ID
NCT02096107
Phase
Phase 4
Status
Completed
Drug / intervention
Everolimus
Sponsor
Medical University of South Carolina
Start
2014-02
Enrollment
60
Locations
1
About this trial
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in Glomular Filtration Rate (GFR) and allograft fibrosis.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02096107 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.